



# The power of public-private collaboration: Institut Pasteur Korea & GlaxoSmithKline

Hakim Djaballah, PhD  
Chief Executive Officer



Institut Pasteur Korea

*We are Pasteurians fighting disease in Korea for all mankind*



*Unleashing the*

# **X** The power of public-private collaboration: Institut Pasteur Korea & GlaxoSmithKline

Hakim Djaballah, PhD  
Chief Executive Officer



Institut Pasteur Korea

*We are Pasteurians fighting disease in Korea for all mankind*

# Mission Statement


---

Institut Pasteur Korea is an ***infectious disease-focused*** research institute that utilizes proprietary platforms to identify novel molecular targets and discover small molecules to diagnose, treat, and address serious ***unmet global public health*** needs




# Institut Pasteur Korea

## Personnel



100 employees  
83 RnD (22 PhD holders)  
17 Admin support

## Funding



# Our research programs

---

- **Tuberculosis (MDR, XDR, & dormant)**
- **Super bacteria & antimicrobial resistance**
- **Leishmaniasis**
  
- **Viral hepatitis (Hep C & Hep B)**
- **Respiratory viruses (Influenza)**
- **Dengue fever**
  
- **Hepatocellular carcinoma**
  
- **Ebola**
- **Malaria**
- **MERS-CoV**



# We are members of a larger global presence



# Our global partners



World Health Organization



# Joining forces to fight Tb

## Pulmonary disease caused by mycobacteria

Aerobic, non-motile bacteria, *Mycobacterium tuberculosis*

Highly contagious, Spread in dried droplets

Infectious dose: < 10 bacilli

Bacilli can survive for 6 to 8 months in sputum

## Global data in 2013

1.5 million deaths; 9 million new infections



1.1 million were HIV+

56% were in the South-East Asia and Western Pacific Regions





# Joining forces to fight Tb



# Joining forces to fight Tb


## First line therapy

INH, RIF, PZA, EMB


Introduced in 1960s!

For 2 months, then INH + RIF for at least 4 months


Isoniazid




Rifampicin



Pyrazinamide



Ethambutol



## Second line therapy

For drug-resistant strains (MDR, XDR)

Treatment usually last 6 to 9 months

50-years old drugs



Lengthy treatment  
(2 to 6 months)



High adverse effects




Low compliance



Resistance on the  
rise



# Situation in Asia & Korea



# Institut Pasteur Korea & GlaxoSmithKline




2010 – Technology development for drug discovery

2011 – Tackling MDR/XDR-Tb

2012 – Oxadiazole compound series to fight Tb

2013 – Tackling MDR/XDR-Tb

2014 – Oxadiazole compound series to fight Tb



We welcome the  
opportunity to collaborate  
or discuss opportunities  
with you

